SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
PRAH
--
0.00%
--
Is PRA Health Sciences Inc (PRAH) A Good Stock To Buy?
Insider Monkey · 2h ago
Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign
Investor's Business Daily · 2d ago
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2020 Update
Seeking Alpha - Article · 5d ago
Why Is PRA Health Sciences (PRAH) Up 7.3% Since Last Earnings Report?
Zacks · 05/30 16:31
Edited Transcript of PRAH earnings conference call or presentation 1-May-20 1:00pm GMT
Q1 2020 PRA Health Sciences Inc Earnings Call
Thomson Reuters StreetEvents · 05/11 02:30
UBS Maintains Neutral on PRA Health Sciences, Lowers Price Target to $101
UBS maintains PRA Health Sciences (NASDAQ:PRAH) with a Neutral and lowers the price target from $103 to $101.
Benzinga · 05/05 14:38
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates
Zacks · 05/04 14:29
Baird Maintains Outperform on PRA Health Sciences, Lowers Price Target to $101
Baird maintains PRA Health Sciences (NASDAQ:PRAH) with a Outperform and lowers the price target from $106 to $101.
Benzinga · 05/04 12:35
PRA Health Sciences Inc (PRAH) Q1 2020 Earnings Call Transcript
Motley Fool · 05/02 00:01
PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/01 19:23
Credit Suisse Maintains Outperform on PRA Health Sciences, Lowers Price Target to $113
Credit Suisse maintains PRA Health Sciences (NASDAQ:PRAH) with a Outperform and lowers the price target from $122 to $113.
Benzinga · 05/01 12:40
Guggenheim likes Seattle Genetics in premarket analyst action
Seeking Alpha - Article · 05/01 11:42
William Blair Downgrades PRA Health Sciences to Market Perform
William Blair analyst John Kreger downgrades PRA Health Sciences (NASDAQ:PRAH) from Outperform to Market Perform.
Benzinga · 05/01 09:58
PRA Health Sciences EPS beats by $0.05, beats on revenue
PRA Health Sciences (NASDAQ:PRAH): Q1 Non-GAAP EPS of $1.05 beats by $0.05; GAAP EPS of $0.63 beats by $0.05. Revenue of $783.71M (+8.5% Y/Y) beats by $34.
seekingalpha · 05/01 01:02
PRA Health Sciences (PRAH) Surpasses Q1 Earnings and Revenue Estimates
PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.96% and 3.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/30 23:05
PRA Health Sciences Sees Q2 Sales $705M-$740M Vs. $684.43M Est., EPS $0.75-$0.90 Vs. $0.95 Est.
Benzinga · 04/30 20:10
PRA Health Sciences Withdraws Full-Year FY20 Guidance
Benzinga · 04/30 20:09
PRA Health Sciences Q1 EPS $1.050 Beats $1.020 Estimate, Sales $783.708M Beat $757.010M Estimate
PRA Health Sciences (NASDAQ:PRAH) reported quarterly earnings of $1.050 per share which beat the analyst consensus estimate of $1.020 by 2.94 percent. This is a 4.55 percent decrease over earnings of $1.100 per share
Benzinga · 04/30 20:09
PRA Health Sciences Q1 2020 Earnings Preview
Seeking Alpha - Article · 04/29 21:35
Will PRA Health Sciences (PRAH) Beat Estimates Again in Its Next Earnings Report?
Zacks · 04/29 17:10